Evidence map›Paper›PMID 41410782›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2025

Preclinical evaluation of [

Franziska Zajicek, Liesbeth Everix, Annemie Van Eetveldt, Jeroen Verhaeghe, Stef De Lombaerde, Alan Miranda, Jordy Akkermans, Celia Dominguez, Vinod Khetarpal, Jonathan Bard and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. In Vivo PET Imaging of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Franziska ZajicekMolecular Imaging Center Antwerp (MICA), University of Antwerp, Antwerp, Belgium.ORCID http://orcid.org/0000-0001-5410-687X
Liesbeth EverixMolecular Imaging Center Antwerp (MICA), University of Antwerp, Antwerp, Belgium.ORCID http://orcid.org/0000-0001-5985-1609
Annemie Van EetveldtMolecular Imaging Center Antwerp (MICA), University of Antwerp, Antwerp, Belgium.ORCID http://orcid.org/0000-0002-6488-5456
Jeroen VerhaegheMolecular Imaging Center Antwerp (MICA), University of Antwerp, Antwerp, Belgium.ORCID http://orcid.org/0000-0002-4493-1902
Stef De LombaerdeMolecular Imaging Center Antwerp (MICA), University of Antwerp, Antwerp, Belgium.ORCID http://orcid.org/0000-0002-5307-3575
Alan MirandaMolecular Imaging Center Antwerp (MICA), University of Antwerp, Antwerp, Belgium.ORCID http://orcid.org/0000-0002-5381-015X
Jordy AkkermansMolecular Imaging Center Antwerp (MICA), University of Antwerp, Antwerp, Belgium.ORCID http://orcid.org/0000-0002-1533-9504
Celia DominguezCHDI Management, Inc., the company that manages the scientific activities of, CHDI Foundation, Inc , Los Angeles, CA, USA.
Vinod KhetarpalCHDI Management, Inc., the company that manages the scientific activities of, CHDI Foundation, Inc , Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-2175-5117
Jonathan BardCHDI Management, Inc., the company that manages the scientific activities of, CHDI Foundation, Inc , Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-5097-1361
Longbin LiuCHDI Management, Inc., the company that manages the scientific activities of, CHDI Foundation, Inc , Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-3995-0196
Steven StaelensMolecular Imaging Center Antwerp (MICA), University of Antwerp, Antwerp, Belgium.ORCID http://orcid.org/0000-0003-3376-0519
Daniele BertoglioµNeuro Research Center of Excellence, University of Antwerp, Antwerp, Belgium. daniele.bertoglio@uantwerpen.be.ORCID http://orcid.org/0000-0003-4205-5432

Funding

CHDI Foundation A-11627Fonds Wetenschappelijk Onderzoek 1229721N
6 · The paper itself

Abstract

Huntington's disease (HD) is a neurodegenerative disorder caused by an expanded trinucleotide repeat in the huntingtin gene (HTT) that subsequently leads to aggregation of the mutant huntingtin (mHTT) protein. Thus, lowering mHTT is a key therapeutic approach used by several candidate therapeutics currently under investigation. Visualization of the efficiency of these therapeutics through in vivo mHTT quantification rises in importance. For positron emission tomography (PET) imaging of mHTT aggregates, it is critical to characterize the in vivo kinetic profile of newly identified mHTT binders to assess their translational application. Here, we report the evaluation of [

Indexed as

Carbon RadioisotopesHuntingtin ProteinHuntington DiseaseRadiopharmaceuticalsAnimalsBrainDisease Models, AnimalHumansMaleMiceMice, TransgenicMutationPositron-Emission TomographyProtein AggregatesCarbon RadioisotopesHuntingtin ProteinProtein AggregatesRadiopharmaceuticals[11C]CHDI-009RHuntington’s diseaseKinetic modelingmHTT aggregatesPositron Emission TomographyzQ175DN

Identifiers

PMID41410782
PMCPMC12715049

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.